Kanjinti (trastuzumab-anns) Injection, 420 mg/14 mL Multi-Dose Vial
Kanjinti is a biosimilar to Herceptin (trastuzumab) indicated for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer. Each multi-dose vial contains 420 mg of trastuzumab-anns in 14 mL (30 mg/mL) solution for intravenous infusion. This product is supplied as a single multi-dose vial and requires reconstitution and dilution prior to administration.
Vendor Pricing Comparison
Sorted by lowest price · Add now, sign in at checkout
Vendor Pricing Comparison
Sorted by lowest price · Add now, sign in at checkout
Kanjinti is a biosimilar to Herceptin (trastuzumab) indicated for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer. Each multi-dose vial contains 420 mg of trastuzumab-anns in 14 mL (30 mg/mL) solution for intravenous infusion. This product is supplied as a single multi-dose vial and requires reconstitution and dilution prior to administration.
1 vendor
